Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the ...
April 18 2018 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present new
magnetic resonance imaging (MRI) data from the open-label extension
MoveDMD trial of edasalonexent (CAT-1004) for the treatment of
Duchenne muscular dystrophy (DMD) at the American Academy of
Neurology 70th Annual Meeting to be held April 21 – 27, 2018, in
Los Angeles, CA, at the Los Angeles Convention Center.
Richard Finkel, M.D., Chief, Division of Neurology, Department
of Pediatrics at Nemours Children’s Health System and a Principal
Investigator for the study, will give an oral presentation titled
“MoveDMD®: Positive Effects of Edasalonexent, an NF-ĸB Inhibitor,
in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in
Phase 2 Study with an Open-Label Extension” during the S29 session
“Child Neurology and Developmental Neurology” on Wednesday, April
25, 2018 from 2:00pm – 2:12pm PT.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule that is being developed as a potential disease-modifying
therapy for all patients affected by DMD, regardless of their
underlying mutation. Edasalonexent inhibits NF-kB, a protein that
is activated in DMD and drives inflammation and fibrosis, muscle
degeneration and suppresses muscle regeneration. Edasalonexent
continues to be dosed in the open-label extension of the MoveDMD
Phase 2 clinical trial and Catabasis is preparing for a single
global Phase 3 trial to evaluate the efficacy and safety of
edasalonexent for registration purposes, dependent on raising
capital. The FDA has granted orphan drug, fast track and rare
pediatric disease designations and the European Commission has
granted orphan medicinal product designation to edasalonexent for
the treatment of DMD. For a summary of clinical results reported
to-date, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our SMART
(Safely Metabolized And Rationally Targeted) Linker drug discovery
platform enables us to engineer molecules that simultaneously
modulate multiple targets in a disease. Our lead program in
development is edasalonexent for the treatment of Duchenne muscular
dystrophy. For more information on edasalonexent and our pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180418005043/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024